Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 99

1.

Preclinical evaluation of potential therapeutic targets in dedifferentiated liposarcoma.

Hanes R, Grad I, Lorenz S, Stratford EW, Munthe E, Reddy CC, Meza-Zepeda LA, Myklebost O.

Oncotarget. 2016 Aug 23;7(34):54583-54595. doi: 10.18632/oncotarget.10518.

2.

Amplification of FRS2 and activation of FGFR/FRS2 signaling pathway in high-grade liposarcoma.

Zhang K, Chu K, Wu X, Gao H, Wang J, Yuan YC, Loera S, Ho K, Wang Y, Chow W, Un F, Chu P, Yen Y.

Cancer Res. 2013 Feb 15;73(4):1298-307. doi: 10.1158/0008-5472.CAN-12-2086. Epub 2013 Feb 7.

3.

High-resolution genomic mapping reveals consistent amplification of the fibroblast growth factor receptor substrate 2 gene in well-differentiated and dedifferentiated liposarcoma.

Wang X, Asmann YW, Erickson-Johnson MR, Oliveira JL, Zhang H, Moura RD, Lazar AJ, Lev D, Bill K, Lloyd RV, Yaszemski MJ, Maran A, Oliveira AM.

Genes Chromosomes Cancer. 2011 Nov;50(11):849-58. doi: 10.1002/gcc.20906. Epub 2011 Jul 26.

PMID:
21793095
4.

Preclinical Evaluation of the Pan-FGFR Inhibitor LY2874455 in FRS2-Amplified Liposarcoma.

Hanes R, Munthe E, Grad I, Han J, Karlsen I, McCormack E, Meza-Zepeda LA, Stratford EW, Myklebost O.

Cells. 2019 Feb 21;8(2). pii: E189. doi: 10.3390/cells8020189.

5.

Antiproliferative effects of CDK4/6 inhibition in CDK4-amplified human liposarcoma in vitro and in vivo.

Zhang YX, Sicinska E, Czaplinski JT, Remillard SP, Moss S, Wang Y, Brain C, Loo A, Snyder EL, Demetri GD, Kim S, Kung AL, Wagner AJ.

Mol Cancer Ther. 2014 Sep;13(9):2184-93. doi: 10.1158/1535-7163.MCT-14-0387. Epub 2014 Jul 15.

6.

Combined targeting of MDM2 and CDK4 is synergistic in dedifferentiated liposarcomas.

Laroche-Clary A, Chaire V, Algeo MP, Derieppe MA, Loarer FL, Italiano A.

J Hematol Oncol. 2017 Jun 19;10(1):123. doi: 10.1186/s13045-017-0482-3.

7.

Frequent amplification of receptor tyrosine kinase genes in welldifferentiated/ dedifferentiated liposarcoma.

Asano N, Yoshida A, Mitani S, Kobayashi E, Shiotani B, Komiyama M, Fujimoto H, Chuman H, Morioka H, Matsumoto M, Nakamura M, Kubo T, Kato M, Kohno T, Kawai A, Kondo T, Ichikawa H.

Oncotarget. 2017 Feb 21;8(8):12941-12952. doi: 10.18632/oncotarget.14652.

8.

Differential diagnosis of atypical lipomatous tumor/well-differentiated liposarcoma and dedifferentiated liposarcoma: utility of p16 in combination with MDM2 and CDK4 immunohistochemistry.

Kammerer-Jacquet SF, Thierry S, Cabillic F, Lannes M, Burtin F, Henno S, Dugay F, Bouzillé G, Rioux-Leclercq N, Belaud-Rotureau MA, Stock N.

Hum Pathol. 2017 Jan;59:34-40. doi: 10.1016/j.humpath.2016.08.009. Epub 2016 Sep 3.

9.
10.

Dedifferentiated liposarcoma and pleomorphic liposarcoma: a comparative study of cytomorphology and MDM2/CDK4 expression on fine-needle aspiration.

Mariño-Enríquez A, Hornick JL, Dal Cin P, Cibas ES, Qian X.

Cancer Cytopathol. 2014 Feb;122(2):128-37. doi: 10.1002/cncy.21362. Epub 2013 Nov 12.

11.

SAR405838: A Novel and Potent Inhibitor of the MDM2:p53 Axis for the Treatment of Dedifferentiated Liposarcoma.

Bill KL, Garnett J, Meaux I, Ma X, Creighton CJ, Bolshakov S, Barriere C, Debussche L, Lazar AJ, Prudner BC, Casadei L, Braggio D, Lopez G, Zewdu A, Bid H, Lev D, Pollock RE.

Clin Cancer Res. 2016 Mar 1;22(5):1150-60. doi: 10.1158/1078-0432.CCR-15-1522. Epub 2015 Oct 16.

12.

MDM2 and CDK4 immunostainings are useful adjuncts in diagnosing well-differentiated and dedifferentiated liposarcoma subtypes: a comparative analysis of 559 soft tissue neoplasms with genetic data.

Binh MB, Sastre-Garau X, Guillou L, de Pinieux G, Terrier P, Lagacé R, Aurias A, Hostein I, Coindre JM.

Am J Surg Pathol. 2005 Oct;29(10):1340-7.

PMID:
16160477
13.

An experimental model for the study of well-differentiated and dedifferentiated liposarcoma; deregulation of targetable tyrosine kinase receptors.

Peng T, Zhang P, Liu J, Nguyen T, Bolshakov S, Belousov R, Young ED, Wang X, Brewer K, López-Terrada DH, Oliveira AM, Lazar AJ, Lev D.

Lab Invest. 2011 Mar;91(3):392-403. doi: 10.1038/labinvest.2010.185. Epub 2010 Nov 8.

14.

FGFR genetic alterations predict for sensitivity to NVP-BGJ398, a selective pan-FGFR inhibitor.

Guagnano V, Kauffmann A, Wöhrle S, Stamm C, Ito M, Barys L, Pornon A, Yao Y, Li F, Zhang Y, Chen Z, Wilson CJ, Bordas V, Le Douget M, Gaither LA, Borawski J, Monahan JE, Venkatesan K, Brümmendorf T, Thomas DM, Garcia-Echeverria C, Hofmann F, Sellers WR, Graus-Porta D.

Cancer Discov. 2012 Dec;2(12):1118-33. doi: 10.1158/2159-8290.CD-12-0210. Epub 2012 Sep 20.

15.

Clinical and biological significance of CDK4 amplification in well-differentiated and dedifferentiated liposarcomas.

Italiano A, Bianchini L, Gjernes E, Keslair F, Ranchere-Vince D, Dumollard JM, Haudebourg J, Leroux A, Mainguené C, Terrier P, Chibon F, Coindre JM, Pedeutour F.

Clin Cancer Res. 2009 Sep 15;15(18):5696-703. doi: 10.1158/1078-0432.CCR-08-3185. Epub 2009 Sep 8.

16.

Drug synergy screen and network modeling in dedifferentiated liposarcoma identifies CDK4 and IGF1R as synergistic drug targets.

Miller ML, Molinelli EJ, Nair JS, Sheikh T, Samy R, Jing X, He Q, Korkut A, Crago AM, Singer S, Schwartz GK, Sander C.

Sci Signal. 2013 Sep 24;6(294):ra85. doi: 10.1126/scisignal.2004014.

17.

High amplification levels of MDM2 and CDK4 correlate with poor outcome in patients with dedifferentiated liposarcoma: A cytogenomic microarray analysis of 47 cases.

Ricciotti RW, Baraff AJ, Jour G, Kyriss M, Wu Y, Liu Y, Li SC, Hoch B, Liu YJ.

Cancer Genet. 2017 Dec;218-219:69-80. doi: 10.1016/j.cancergen.2017.09.005. Epub 2017 Sep 22.

PMID:
29153098
18.

Prognostic value of HMGA2, CDK4, and JUN amplification in well-differentiated and dedifferentiated liposarcomas.

Saâda-Bouzid E, Burel-Vandenbos F, Ranchère-Vince D, Birtwisle-Peyrottes I, Chetaille B, Bouvier C, Château MC, Peoc'h M, Battistella M, Bazin A, Gal J, Michiels JF, Coindre JM, Pedeutour F, Bianchini L.

Mod Pathol. 2015 Nov;28(11):1404-14. doi: 10.1038/modpathol.2015.96. Epub 2015 Sep 4.

19.

FGFR2 is overexpressed in myxoid liposarcoma and inhibition of FGFR signaling impairs tumor growth in vitro.

Künstlinger H, Fassunke J, Schildhaus HU, Brors B, Heydt C, Ihle MA, Mechtersheimer G, Wardelmann E, Büttner R, Merkelbach-Bruse S.

Oncotarget. 2015 Aug 21;6(24):20215-30.

20.

Correlation of histological grade of dedifferentiation with clinical outcome in 55 patients with dedifferentiated liposarcomas.

Dantey K, Schoedel K, Yergiyev O, Bartlett D, Rao UNM.

Hum Pathol. 2017 Aug;66:86-92. doi: 10.1016/j.humpath.2017.02.015. Epub 2017 Mar 12.

PMID:
28300575

Supplemental Content

Support Center